Occudo Quantitative Strategies’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Occudo Quantitative Strategies’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,281	Closed	-$25.6K	–	1279
2022 Q4	$25.6K	Sell	1,281 -75	-6%	-$1.49K	﹤0.01%	910
2022 Q3	$24K	Hold	1,356	–	–	﹤0.01%	1126
2022 Q2	$30K	Sell	1,356 -8	-0.6%	-$178	﹤0.01%	1089
2022 Q1	$38K	Hold	1,364	–	–	﹤0.01%	1088
2021 Q4	$62K	Buy	1,364 +263	+24%	+$17.7K	0.01%	1001
2021 Q3	$92K	Buy	1,101 +301	+38%	+$24.9K	0.01%	926
2021 Q2	$76K	Buy	800 +221	+38%	+$26.2K	0.01%	822
2021 Q1	$96K	Buy	+579	New	+$76.6K	0.02%	691

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Occudo Quantitative Strategies's ONCT Position: Q1 2023 in Review

Occudo Quantitative Strategies sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2023, closing a stake of 1,281 shares — an estimated $25.6K sold.

Occudo Quantitative Strategies first reported a position in ONCT in Q1 2021 and held it in 8 quarters. The position peaked at $96K in Q1 2021. 54 funds tracked by Wall St. Rank hold ONCT as of Q1 2023.

Occudo Quantitative Strategies reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Occudo Quantitative Strategies sold 1,281 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $25.6K.
Occudo Quantitative Strategies first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Occudo Quantitative Strategies's Oncternal Therapeutics, Inc. Common Stock position peaked at $96K in Q1 2021.
54 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2023, filed 15 May 2023.